Protagonist Therapeutics

Protagonist Therapeutics

Yahoo Finance • 10 days ago

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokima... Full story

Yahoo Finance • 13 days ago

J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has risen 18.3% in the past three months, backed by improving earnings and sales, a raised 2026 outlook, strong performance from newer medicines, pipeline wins and progress toward reducing the long-running uncer... Full story

Yahoo Finance • 23 days ago

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million... Full story

Yahoo Finance • 27 days ago

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additio... Full story

Yahoo Finance • 30 days ago

Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News

Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, in... Full story

Yahoo Finance • last month

Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?

Protagonist Therapeutics (NasdaqGM: PTGX) reported U.S. FDA approval of MIMRYLO (rusfertide) as a first in class hepcidin mimetic peptide for adults with polycythemia vera. The approval makes MIMRYLO the only FDA approved hepcidin mimetic... Full story

Yahoo Finance • last month

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Jo... Full story

Yahoo Finance • last month

Better Growth Stock ETF: Vanguard's Large-Cap VUG vs. Invesco's Small-Cap RZG

The Vanguard Morningstar Growth ETF (NYSEMKT:VUG) provides ultra-low-cost exposure to domestic large-cap growth stocks, whereas the Invesco S&P SmallCap 600 Revenue ETF (NYSEMKT:RZG) targets small-cap growth companies by weighting them acc... Full story

Yahoo Finance • last month

J&J's Strong Pipeline Momentum Offers Multiple Growth Catalysts Ahead

Johnson & Johnson's JNJ pipeline is becoming an increasingly important growth driver as the company looks to offset future pressure from mature products such as Stelara and eventually Darzalex. The company has a particularly strong set of... Full story

Yahoo Finance • 4 months ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 4 months ago

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key Points ADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing. Quarter-end position value increased by $26.98 million, reflecting both trading... Full story

Yahoo Finance • 5 months ago

Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ranks 10th on this list. Elite investors have been positioning themselves in Protagonist Therapeutics... Full story

Yahoo Finance • 5 months ago

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

DelveInsight Business Research LLP The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ionis P... Full story

Yahoo Finance • 6 months ago

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results further support the differentiated profil... Full story

Yahoo Finance • 6 months ago

Do Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Growth Index... Full story

Yahoo Finance • 6 months ago

US High Growth Tech Stocks to Watch Now

Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companie... Full story

Yahoo Finance • 6 months ago

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story

Yahoo Finance • 6 months ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • 6 months ago

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrate... Full story

Yahoo Finance • 7 months ago

FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug Application and granted Priority Review for rus... Full story